Recall of YoCrunch Yogurt Due to Potential Plastic Contamination

Danone U.S. has issued a voluntary recall of YoCrunch yogurt due to reports of small plastic pieces found in the dome toppers, posing choking and injury risks. Consumers should check their products and contact the company for refunds.
In a recent safety alert, Danone U.S., the manufacturer of YoCrunch yogurt, announced a voluntary recall of various products distributed across the United States. This action comes after reports of small, sharp plastic pieces found inside the dome-shaped toppers that adorn some yogurt containers. The presence of these plastic fragments poses a risk of choking or injury if consumed, prompting immediate removal from store shelves.
The affected products include all flavors and sizes of YoCrunch yogurt with expiration dates spanning from early July to early September. It's important to note that the yogurt itself remains safe to eat; the concern lies solely with the plastic components in the topper domes.
According to reports, customers have identified transparent plastic pieces within the dome lids, which are typically used to hold toppings like cookies or candy. In response, Danone U.S. is working closely with retail partners to expedite the recall process. Consumers who have purchased affected products are advised not to consume them and should contact the company's dedicated hotline at 877-344-4886 for refund details.
This recall highlights the company's commitment to product safety and quality. Danone assures the public that they are actively addressing the issue to prevent further incidents and to restore consumer confidence in their products.
For more detailed information about the recall, visit the official FDA recall notice. Consumers are encouraged to stay informed and prioritize safety when handling food products, especially those involving packaging components.
Source: https://medicalxpress.com/news/2025-07-popular-yocrunch-yogurt-recalled-plastic.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Promising Results from Shortened Immunotherapy Duration for Advanced Melanoma in Clinical Trial
A groundbreaking clinical trial suggests that stopping immunotherapy after one year may be as effective as two years for advanced melanoma, potentially reducing side effects and treatment burden.
Innovative Drug Shows Promise in Managing Resistant Hypertension
A new clinical trial highlights lorundrostat's potential to safely lower blood pressure in patients with resistant hypertension, marking a significant advancement in targeted hypertension therapy.
The True Leading Risk Factor for Cancer: Aging
Aging is the most significant and unavoidable risk factor for cancer. As the population ages rapidly, healthcare systems must adapt with specialized, patient-centered approaches to improve cancer care and outcomes for older adults.